Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RRx-001 + WBRT in Brain Metastases
NCT02215512Phase 1Completed
- Sponsor
- EpicentRx
- Start
- Feb 2015
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Nibrozetone in brain metastases, sponsored by EpicentRx. Primary endpoint: Number, frequency and type of adverse events at 42 days. Started Feb 2015; status: completed.
02
Drugs
Nibrozetone
03
Conditions
brain metastases
Beyond the preview
Go deeper on NCT02215512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02215512.